AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04824092 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT04824092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT05190705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab Tesirine
Description: Administered by intravenous infusion
Study NCT05190705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Taken orally or administered by intravenous infusion
Study NCT06025240 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cf-DNA
Description: In addition to the standard of care tests, participants will have an additional blood sample (dd-cf DNA). A cohort study patients who have undergone high immunological risk kidney transplant at our centre defined as a re-transplant, where the cRF is >20% or where there is a level 4 HLA-mismatch. We will take a single plasma sample for dd-cfDNA testing at 6-12 months post-transplant and pair this with an assessment of renal function (creatinine, eGFR), MSU, BK and CMV PCR, single antigen bead (SAB) monitoring of HLA-specific antibodies and allograft USS.
Study NCT06025240 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Immunological Events following renal transplant in older age
Description: Determine the overall frequency of immunological events and de novo HLA specific antibody formation in the \<60 and >60 age population. Standard of care test taken at the different time intervals for routine storage. We will use those samples for HLA testing (either screening alone or screening and single antigen bead testing if screening yields a positive result).
Study NCT06025240 — intervention group
Intervention type: OTHER
Intervention: Determining Predictive Models for Post-transplant HLA-specific Antibody Formation
Description: A machine learning model will be developed in Python using a range of pre- and post-transplant variables to determine a predictive model for de novo HLA-specific antibody following renal transplant.
Study NCT04824092 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT04824092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT04824092 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT06584123 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-Fluoro-ethyl-tyrosine (FET) PET
Description: 18F-Fluoro-ethyl-tyrosine PET study of the pituitary
Study NCT06583681 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: The measuring of the sagittal curvatures of the spine
Description: Research tool was Baseline Bubble inclinometer.
Study NCT04824092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT04824092 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vincristine
Description: Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT04824092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT04824092 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Prednisone PO will be administered as per the schedule specified in the respective arm.
Study NCT04824092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone PO will be administered as per the schedule specified in the respective arm.
Study NCT05150938 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.
Study NCT05150938 — intervention group
Intervention type: DRUG
Intervention: Low molecular weight heparin (LMWH)
Description: Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.
Study NCT05150938 — intervention group
Intervention type: DRUG
Intervention: vitamin K antagonist (VKA)
Description: Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.
Study NCT05150938 — intervention group
Intervention type: DRUG
Intervention: other NOACs
Description: Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.
Study NCT06296485 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAGE Group Sessions
Description: Participants enroll in 3 educational group sessions and receive CGMs
Study NCT06296485 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants continue to receive usual care (Control Arm)
Study NCT04968184 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will orally receive placebo matching to KBP-5074 tablets QD.
Study NCT04968184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-5074
Description: Participants will orally receive KBP-5074 tablets, from 0.25 mg to a maximum dose of 0.5-mg QD.
Study NCT05318872 — intervention group
Intervention type: DEVICE
Intervention: ENDOSWIR
Description: Patients were enrolled for surgery of their cancer and give their consents to the participation to that study. Characteristics of anonymized patient (sex, age, medical history, and tumoral characteristics) will be collected. During surgery, the excisional specimen will be sent in a fresh state for pathological examination (gold standard). The pathologist will determine 10 zones on a cross-section of the specimen which will be analyzed by SWIR, and compared between the two techniques.
Study NCT05218525 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Algorithm
Description: Participants in the intervention group will receive the general offer of the telehealth intervention including the telehealth system with the implemented COPD prediction algorithm. The participants are asked to measure their vital signs and respond to COPD related questions as usual. As usual refers to fixed days in the week, either Monday or Thursday, where the participants must measure their vital signs. In addition, the participants must weekly measure two oxygen saturation measurements drawn from the fingertip pulse oximeter.
Study NCT05830071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF5993
Description: BDP/FF/GB 100/6/12.5 μg pMDI
Study NCT05830071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF5259
Description: GB 12.5 μg pMDI
Study NCT05830071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400mg
Description: 400 mg Oral Tablets
Study NCT05830071 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CHF5993 Placebo
Description: placebo pMDI
Study NCT04824092 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tafasitamab placebo
Description: 0.9% saline solution IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT05830071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF5993 Placebo
Description: placebo pMDI
Study NCT04824092 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lenalidomide placebo
Description: Placebo matching to lenalidomide PO will be administered as per the schedule specified in the respective arm.
Study NCT05762406 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory protective mask
Description: Subjects will perform a cardiopulmonary exercise test (CPET) and a series of standardized daily activities while wearing a protective mask.~During the exercises, oxygen consumption, ventilation and other cardiorespiratory parameters will be assessed using a portable device (K5, Cosmed)
Study NCT05748457 — intervention group
Intervention type: BEHAVIORAL
Intervention: Non-manualised family therapy.
Description: Family therapy provided by qualified therapists without reference to a specific therapy manual.
Study NCT05748457 — intervention group
Intervention type: BEHAVIORAL
Intervention: Family Based Treatment
Description: Family therapy implemented according to the published Treatment manual for anorexia nervosa: A family-based approach by Lock \& Le Grange (2nd edition, 2015).
Study NCT05393973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stability exercises along with conventional physical therapy
Description: Core stability exercises included neck isometric exercises(flexion, extension, lateral flexion, rotation), chin tuck, chin tuck into towel, cervical extension + 10 minutes hot pack+ 10 minutes stretching (cervical flexors, extensors, rotators), session will be of 30-40 minutes, three times a week, for 4 weeks duration.~Chin Tuck: In standing subject pulls back the chin( as if trying to make a double chin) while keeping the eyes level. This will be done for 15 repetitions.~Cervical extension: In a standing position, the subject grasps the base of the neck, with both hands while extending the neck as far as possible. This will be done for 15 repetitions
Study NCT05393973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swiss ball exercises along with the conventional physical therapy protocol
Description: Swiss ball exercise will be executed in the following order, assume supine posture on the treatment bed by fully extending their legs and putting them back on the bed in the most comfortable posture with hands on the abdomen. Second, while in the supine posture, support the head with one hand and insert a small Swiss ball near the back of the head with the other hand. Third, after having contacted the ball to the area below the back of the head, slowly turn the head and neck in the shape of the number '8'. Fourth, after having set 3 repetitions of rotating the head and neck for 10 seconds and then taking 10 seconds of general resting as 1 set of exercise, a total of 3 sets of exercise were executed with 1 minute of general resting taken between each set of exercise. Then perform neck flexion, extension, side bending, and rotation, hold each movement for 10 seconds + Hot pack (10 minutes) + 10 minutes of cervical stretching. Perform the exercise three times a week for 4 weeks duration.
Study NCT04868760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Drug: Ipilimumab 0.1 mg/kg and 0.3 mg/kg in preparatory experiments and 0.3 mg/kg in formal experiment.
Study NCT04936711 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resteck Shiatsu Neck and Back Massager
Description: back massager device sold on the market that can readily be purchased online or in store
Study NCT04936711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcaine
Description: Marcaine spray at incision site after closure
Study NCT04868760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI310
Description: Drug: IBI310 0.1 mg/kg and 0.3 mg/kg in preparatory experiments and 0.3 mg/kg in formal experiment.
Study NCT05101668 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracranial Thrombosis Aspiration Catheter
Description: Direct Aspiration
Study NCT06253169 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HPV DNA self-test
Description: HPV DNA swab from the cervix performed by the patient herself.
Study NCT06409442 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physiotherapy Program
Description: Patients with Subacromial Impingement Syndrome (SIS) will receive a 6-week treatment program. Patients will be given a physiotherapy treatment program by a physiotherapist three times a week, and on the other days, patients will practice six selected simple exercises at home.
Study NCT06409442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Physiotherapy Program
Description: Patients with Subacromial Impingement Syndrome (SIS) will receive a 6-week treatment program. Patients will be given a physiotherapy treatment program by a physiotherapist three times a week, and on the other days, patients will practice six selected simple exercises at home.
Study NCT06409442 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Taping
Description: In addition to the standard physiotherapy program, kinesio taping (device) will be applied.
Study NCT06409442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local Vibration Therapy
Description: In addition to the standard physiotherapy program, local vibration (device) will be applied.
Study NCT05299840 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oncogramme results available
Description: in vitro analysis of each patient's tumor cells in order to compare the responses of the tumor cells to the different molecules and therapeutic combinations available
Study NCT05299840 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Oncogramme results unavailable
Description: in vitro analysis of each patient's tumor cells in order to compare the responses of the tumor cells to the different molecules and therapeutic combinations available
Study NCT06359977 — intervention group
Intervention type: OTHER
Intervention: Quantitative EEG monitoring and beside ultrasound evaluation
Description: After successful spontaneous breathing trial, neurocritical patients undergo at least 2 hours of quantitative EEG monitoring before extubation. Additionally, bedside ultrasound assesses the thickness and variability of the diaphragm, intercostal muscles, rectus abdominis, transversus abdominis, and external oblique muscles. The sputum volume for the 24 hours prior to extubation is also recorded. Reintubation within 48 hours after extubation is defined as weaning failure.
Study NCT05734586 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: EAT-10 (Eating assessment Tool) screening questionnaire
Description: After inclusion, issuance of the EAT-10 screening questionnaire for swallowing disorders by the healthcare team
Study NCT05734586 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Protective measures for the upper airways
Description: In the event of an EAT ≥2 score, immediate implementation or within three days by the healthcare team of protective measures for the upper airways in 3 sectors:~1: Postural maneuvers; 2: Hygienodietetic rules; 3: Food textures
Study NCT05884606 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Allurion Digital Behaviour Change Intervention
Description: The Allurion DBCI adheres to current National Institute for Health and Care Excellence (NICE) guidance for obesity.
Study NCT04436965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized nutrition therapy
Description: Standardized nutrition therapy with ONS, nasal feeding tube, PEG or parenteral nutrition
Study NCT04436965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Patients in both arms received concurrent cisplatin chemotherapy:100 mg/m² cisplatin given intravenously every 3 weeks on days 1, 22 concurrently with radiotherapy.
Study NCT05779410 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Participants received 5,000 IU of vitamin D orally twice daily for 4 weeks
Study NCT05779410 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Medium-chain triglycerides
Description: Participants received the same amount of placebo matching vitamin D orally twice daily for 4 weeks
Study NCT04796454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin IV 25 mg/m² on d1 and d8 - always combined with Gemcitabine; maximum treatment 2 years
Study NCT04796454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine IV 1000 mg/m² on d1 and d8 if in combination with Cisplatin; Gemcitabine IV 1000 mg/m² on d1 and d15 if in combination with Oxaliplatin; maximum treatment 2 years
Study NCT04796454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin IV 100 mg/m² on d1 and d15 - always combined with Gemcitabine; maximum treatment 2 years
Study NCT04796454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Description: Pamiparib 60 mg PO twice a day from d1 to day28 in a 4-week cycle - always combined with Temozolomide; until progression or maximum treatment 2 years
Study NCT04796454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide 60 mg PO once a day from d1 to d7 in a 4-week cycle - always combined with Pamiparib; until progression or maximum treatment 2 years
Study NCT05804344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal speech motor tDCS
Description: tDCS montage set for Anode: C5; Cathode: Fp2
Study NCT05804344 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cathodal speech motor tDCS
Description: tDCS montage set for Anode: Fp2; Cathode: C5
Study NCT05804344 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anodal IFG tDCS
Description: tDCS montage set for Anode: F3; Cathode: Fp2
Study NCT05804344 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cathodal IFG tDCS
Description: tDCS montage set for Anode: Fp2; Cathode: F3
Study NCT05804344 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: tDCS device set in Sham mode
Study NCT05030506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: 40 mg tablet administered orally at a dose of 120 mg
Study NCT05030506 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 25 mg/mL solution for Infusion in a single-dose vial administered intravenously at a dose of 400 mg
Study NCT05030506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 10 mg capsule administered orally at a dose of 20 mg
Study NCT06323460 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06323460 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06323460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT06323460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT06323460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT06323460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study NCT06323460 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT06323460 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT06323460 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo external beam radiotherapy
Study NCT06323460 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External Beam Radiation Therapy
Description: Undergo external beam radiotherapy
Study NCT06323460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT06323460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study NCT06323460 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT06323460 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT06323460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06323460 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05988398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: READY To Stand Curriculum
Description: Students will receive the RTS programming over six consecutive school days, spread over two weeks. The program is delivered in mixed-gender groups of 20 to 40 students and includes videos, small and large group discussions, activities, worksheets, and ample opportunities for skill-building. This curriculum is intended to be one piece of comprehensive prevention strategies that has the potential to make immediate and sustained impacts on reducing rates of CSEC perpetration in the lives of youth, including those most vulnerable to this pernicious crime.
Study NCT06496009 — intervention group
Intervention type: DRUG
Intervention: PD-1 Inhibitors
Description: advanced or metastatic non-small cell lung cancer who are PD-L1 negative and receiving first-line immunotherapy in routine clinical practice